Hikma Pharmaceuticals (LON:HIK) PT Raised to GBX 1,800 : vim

Hikma Pharmaceuticals (LON:HIK – Get Free Report) had its price objective hoisted by Barclays from GBX 1,700 ($21.87) to GBX 1,800 ($23.16) in a research report issued on Wednesday, Marketbeat.com reports. The firm presently has an “equal weight” rating on the stock. Barclays‘s target price indicates a potential downside of 1.13% from the company’s current […]

Related Keywords

United States , America , , Jefferies Financial Group , Hikma Pharmaceuticals Stock , Hikma Pharmaceuticals Company Profile , News Ratings For Hikma Pharmaceuticals Daily , Barclays , Hikma Pharmaceuticals , Analyst Recommendations For Hikma Pharmaceuticals , Get Free Report , Douglas Hurt , North America , Middle East , North Africa , Hikma Pharmaceuticals Daily , Lon Hik , Zhik , Medical , Boost Price Target , Barclays Plc ,